EVOTEC SE 
General company presentation
Evotec SE, Company presentation, March 2024
Disclaimer
This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the "Company", "we," "our" or "us"). This presentation is made pursuant to Section 5(d) and/or Rule 163B of the Securities Act of 1933, as amended, and is intended solely for investors that are qualified institutional buyers or certain institutional accredited investors solely for the purposes of familiarizing such investors with the Company. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy Evotec securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No representations or warranties, express or implied, are made as to the accuracy or completeness of the statements, estimates, projections or assumptions contained in the presentation, and neither the Company nor any of its directors, officers, employees, affiliates, agents, advisors or representatives shall have any liability relating thereto.
Cautionary Note Regarding Forward-Looking Statements
This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Many of the forward-looking statements contained in this presentation can be identified by the use of forward- looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and other similar expressions that are predictions of or indicate future events and future trends, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on our
management's beliefs and assumptions and on information currently available to our management. Such statements are
subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward- looking statements due to a variety of factors. The forward-looking statements contained in this presentation speak only as of the date of this presentation, and unless otherwise required by law, we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.
PAGE 2
- Together for Medicines that Matter
- PanOmics
- iPSCs
- Just - Evotec Biologics
- End-to-EndShared R&D
- Financials
PAGE 3
The core idea of Evotec - evolutionary technology
"The goal of Evolution is not
one single human, it is mankind."
Eigen's theories about self-organisation of complex molecules and his development of the evolution machine founded a new branch of science - evolutionary biotechnology.
Manfred Eigen (1927-2019)
Co-founder of Evotec, Nobel Prize 1967
PAGE 4 | Evotec was founded 1993 |
Accelerating medicines that matter
About us
4,000++ scientists empowering our partners
Across all disciplines and disease areas from target to commercial manufacturing
Co-creating pipelines
Leveraging our assets, targets or proprietary platforms for licensing, co-development or potential NewCo creation, frequently combining with Partners' programs, and ideas
R&D Biotech that offers accelerated, high-value pipeline co-creation, and R&D solutions
Performance - "Beyond FTEs"
Collaborating with "end in mind", result-driven partnership models
Track record - highest quality, most capital-efficient execution
State-of-the-art services as core offering for partners
PAGE 5
Together for medicines that matter
Game changers for pipeline co-creation
Need for more precision Most drugs still provide benefit in only 50% of patients
Need for better disease understanding More than 30% have a lifetime risk
for cancer
Need for better safety earlier
60% of all drugs still do not pass Phase I
Need for wider access
Less than 20% of world's population have access to life changing biotherapeutics
Better pipeline building
Right indication, right patients, right dose
Technology convergence
A.I./ML coming together with drug discovery, development, safety prediction and molecular diagnostics
Better Access
A.I./M and continuous manufacturing for better access to biologics
Better business models
Shared economy in R&D
- From fixed to variable costs
- More effective learning curves for all
PanOmics
iPSC cell therapy
Just - Evotec Biologics
End-to-End Shared R&D
PAGE 6
New technologies leading to new opportunities
Shaping (new) markets
End-to-End shared R&D
30 | ||
25 | 2x | |
USDbnin | 20 | |
15 | ||
10 | ||
5
0
20222030
Outsourcing
Large Pharma in-house
Drivers
Deteriorating IRRs in-crease demand for outsourcing & higher efficiency
PanOmics | iPSC cell therapy | Biologics |
CAGR | CAGR | |||||||
CAGR | 29% | 12% | ||||||
16 | 1,600 | 80 | ||||||
21% | ||||||||
USDbnin | 12 | USDbnin | 1,200 | USDbnin | 60 | |||
8 | 800 | 40 | ||||||
4 | 400 | 20 | ||||||
0 | 0 | 0 | ||||||
2022 | 2030 | 2022 | 2030 | 2022 | 2030 | |||
Replacing (donor) allogenic therapies | Continuous manufacturing | |||||||
Multi Omics market | iPSC cell therapy | Biologic discovery & manufacturing |
Drivers | Drivers | Drivers | ||
Precise medicines & dia- | From donor dependency | Regulatory changes (e.g. | ||
gnostics leading to patient | to scalable off-the-shelf | IRA*) driving need to in- | ||
specific treatments | solutions | crease agility & flexibility | ||
PAGE 7 | *Inflation Reduction Act |
Sources: Grand View Research; Precedence Research; Mordor Intelligence; SNS Insider; Evaluate Pharma Analysis; Global Market Insights gminsights.com |
A shared economy model in R&D as basis for success
A stable foundation
RoW | |||
>500 | ~38% | 4% | |
Revenue | |||
Active partners | Revenue share with | Europe 35% by region 63% | USA |
TOP 10 partners
NFP, Academic, | ||||
7% | Foundations | |||
>92% | 118 | % | % Biotech | |
Revenue | ||||
Top 20 | ||||
Pharma | ||||
Repeat | No. of partners with | 38 | by partner 42 | |
business | > € 1 m revenues | % | ||
(+22%) | 13 | |||
Large Biotech / | ||||
Mid-sized Pharma |
PAGE 8
Sustainable growth enabled by commitment, culture, values & people
Selected ESG-KPIs
75% | 33% | 31% | ||||||
25% | ||||||||
Evotec SE | Share of PhDs | Women in Leadership | ||||||
Peers without ´ | Peers with | |||||||
SBTi targets | SBTi targets | |||||||
EcoVadis Score | 91 | 46% | ||||||
52% | Men | |||||||
39% | ||||||||
Evotec: 60 | ~5,000x | |||||||
talent | ||||||||
Nationalities | ||||||||
0% | 54% | |||||||
4% | 5% | |||||||
Women | ||||||||
0-2525-45 | 45-6565-8585-100 | |||||||
PAGE 9 | Derived from company information from: Charles River, Catalent, Wuxi Apptech, Wuxi Bio, Sartorius, Lonza, Qiagen, Eurofins, Danaher, Abcellera, Fate Therapeutics, Sana Biotechnology, Schrodinger, Recursion, Exscientia |
Collaborative pipeline building together with our partners
Selected KPIs
# programmes by disease area* | |||
>140 | 18 | Immunology / | ~30% |
Commu- | |||
Inflammation | |||
~10% | Oncology | ||
Co-owned | Clinical | nicable >20% | |
diseases | |||
pipeline assets | stage | ||
~20% | >20% Neuroscience | ||
Metabolic | |||
disease | and Pain |
>€ 15 bn | 8-10% | > 300 programmes by model | ||
>120 | ||||
>95 | ||||
Non-risk-adjusted | Average | >50 | ||
partnership milestones | >45 | |||
royalty rate | ||||
over 20 years | ||||
Partnered Unpartnered | Equity | BRIDGEs |
PAGE 10 | *Partnered & unpartnered, excluding Equity and BRIDGEs |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Evotec SE published this content on 09 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 April 2024 12:07:08 UTC.
